Sihuan Pharmaceutical Executes Key Share Purchase Under Share Award Scheme

Major Highlights for Investors

• Share Purchase: On 27 May 2026, Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical”)’s Trustee acquired 8,000,000 shares on the open market for its Share Award Scheme.
• Share Proportion & Price: The shares purchased represent approximately 0.0877% of the total issued shares (excluding treasury shares), at an average price of HK\$1.0052 per share.
• Strategic Rationale: The board believes that this move is strongly aligned with the company’s profit inflection point, accelerating growth, and incentivizing the core team for long-term value creation.

Business and Financial Performance Overview

In 2025, Sihuan Pharmaceutical delivered robust financial results:

• Total revenue reached RMB2,618.0 million, up 37.7% year-on-year.
• The Group reported a profit of RMB185.4 million, marking a turnaround from previous losses.

The company’s medical aesthetics business emerged as the largest revenue pillar, generating RMB1,485.3 million—a remarkable 99.6% year-on-year increase. This segment now accounts for 57% of total revenue, surpassing the 50% threshold for the first time.

• Flagship, self-developed regenerative medical aesthetics products have received multiple marketing approvals and are in rapid commercialization.
• Global expansion is accelerating, boosted by the Group’s investment in Swiss firm Suisselle, which gives Sihuan a foothold in the European medical aesthetics market via an “overseas investment + resource integration” approach.

Innovative Drug Business and Growth Drivers

The innovative drug segment’s revenue more than doubled year-on-year, entering a “full-scale commercialization harvest period.” Key achievements include:

• Continuous breakthroughs in research and development, market launches, and inclusion in the National Reimbursement Drug List (NRDL).
• Strong momentum for sustainable, long-term development driven by the dual engines of medical aesthetics and biopharmaceuticals.

Shareholder-Relevant and Price-Sensitive Considerations

• The share purchase under the Share Award Scheme is likely to be price sensitive, as it signals management’s confidence in the company’s growth trajectory, aligns the interests of key personnel with shareholders, and could support the share price through both demand and positive sentiment.
• The company’s return to profitability, rapid revenue growth, and aggressive expansion in the medical aesthetics sector (domestically and internationally) are significant value drivers.
• The ongoing commercialization of innovative drugs and product pipeline breakthroughs enhance future earnings visibility.

Company Profile

Listed on the Main Board of the Hong Kong Stock Exchange since 2010, Sihuan Pharmaceutical is an international pharmaceutical and medical aesthetics company with a strong innovation focus. The company boasts an independent R&D platform, a rich global product pipeline, robust product registration capability, efficient manufacturing, and a mature sales system. Sihuan is committed to a “two-wheel drive strategy,” aiming to establish leadership in both medical aesthetics and biopharmaceuticals in China.

Board and Management

• Dr. Che Fengsheng serves as Chairman and Executive Director.
• Other executive directors include Dr. Guo Weicheng (Deputy Chairman and CEO), Dr. Zhang Jionglong, Ms. Chen Yanling, and Ms. Miao Guili.
• Independent non-executive directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun, Mr. Wang Guan.

Key Takeaways for Investors

• This share purchase is a clear demonstration of the company’s confidence in its growth outlook and commitment to value creation for shareholders.
• Strong business performance, rapid growth in the medical aesthetics sector, and breakthroughs in innovative drugs could provide upward momentum for the share price.
• Investors should monitor the ongoing commercialization success, international expansion, and further product approvals as potential catalysts for future value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making investment decisions. The author is not responsible for any actions taken based on the information provided.

四環醫藥股份集團 – 詳盡投資者資訊及公告解讀

重點摘要

• 股份購買：於2026年5月27日，四環醫藥股份集團的信託人於市場購買8,000,000股公司股份，作為股份獎勵計劃用途。
• 股份佔比及價格：是次購買股份佔公司已發行股份（不包括庫藏股）約0.0877%，平均每股作價約為港幣1.0052元。
• 戰略意義：董事會認為，此舉有助於穩定核心團隊、激勵長遠發展，並與公司盈利拐點及高速增長階段高度契合，帶動長期價值創造。

業務表現及財務概覽

• 2025年集團總收入達人民幣26.18億元，同比增長37.7%。
• 成功扭虧為盈，全年錄得純利人民幣1.854億元。

醫美業務成為公司最大支柱，收入達人民幣14.853億元，按年大增99.6%，首次佔總收入逾57%。

• 自研再生醫美產品獲多項上市批文，商業化進程迅速。
• 集團透過投資瑞士Suisselle，進軍歐洲醫美市場，推動“海外投資+資源整合”模式，加速全球擴張。

創新藥業務與增長動力

• 創新藥業務收入按年翻倍，進入全面商業化收穫期，研發、市場推廣及納入國家醫保目錄（NRDL）均取得突破。
• 醫美與生物製藥雙引擎協同發展，為集團可持續增長提供強大動力。

對股東及股價或具影響的重要事項

• 股份獎勵計劃下的股份購買屬潛在敏感消息，顯示管理層對公司前景充滿信心，並通過激勵綑綁核心團隊與股東利益，或對股價帶來正面支持。
• 公司成功扭虧、收入高速增長及醫美業務加速國際化，均屬推動估值的重要因素。
• 創新藥持續商業化、產品管線不斷突破，提升未來盈利能見度。

公司簡介

四環醫藥於2010年於港交所主板上市，為一家以創新為導向的國際醫藥及醫美公司，擁有獨立研發平台、全球化產品管線、強大註冊能力、高效低成本的製造體系及成熟銷售網絡。公司堅持“醫美+生物製藥”雙輪驅動戰略，致力成為中國領先的醫美及生物製藥公司。

董事會及管理層

• 主席兼執行董事：謝鳳生博士
• 執行董事包括：郭衛成博士（副主席兼CEO）、張炯龍博士、陳艷玲女士、苗桂麗女士
• 獨立非執行董事：曾華光先生、朱迅博士、王冠先生

投資者需留意要點

• 本次股份購買顯示公司對發展前景充滿信心，有助於推動公司市值與長遠投資價值提升。
• 業績向好、醫美業務高速增長及創新藥收穫期，均有望為公司帶來進一步上升動力。
• 建議投資者關注未來創新藥商業化進展、國際擴張及新產品獲批等潛在催化劑。

免責聲明：本文僅供參考，並不構成任何投資建議。投資者應自行調查或諮詢專業顧問後作出投資決定，作者對據此作出的任何行動不承擔責任。